News

HUTCHMED Unveils New Clinical Findings at Upcoming Global Conferences

HUTCHMED Unveils New Clinical Findings at Upcoming Global Conferences

HUTCHMED to Present Significant Clinical Data at Global Conferences

HUTCHMED (China) Limited (NASDAQ: HCM; HKEX: 13) is excited to share that new and updated clinical results from various studies will be highlighted at two prestigious oncology conferences. These are the upcoming 2025 World Conference on Lung Cancer (WCLC) in Barcelona and the CSCO Annual Meeting 2025 in Jinan, where groundbreaking research on its innovative therapies will be showcased.

Insight into Savolitinib Studies

One significant feature of the WCLC 2025 is the presentation of updated analyses from studies focusing on savolitinib, an oral MET tyrosine kinase inhibitor co-developed with AstraZeneca. The SACHI, SAVANNAH, and Phase IIIb confirmatory studies will be addressed, specifically looking at their implications for patients with non-small cell lung cancer (NSCLC).

Key Presentations on Savolitinib

The presentations at WCLC will include:

  • SAVANNAH: This presentation will explore biomarker concordance and acquired resistance in patients with specific NSCLC characteristics.
  • Efficacy and Safety of Savolitinib: Focusing on advanced or metastatic METex14 NSCLC patients, the results of this study are essential for understanding treatment effectiveness.
  • Frontline Treatment Duration Insights: Data on treatment duration following failures in third-generation EGFR-TKI therapies will be shared in further detail.

New Research on HMPL-653

At the CSCO Annual Meeting 2025, HUTCHMED will debut clinical data from a Phase I study of HMPL-653, a novel CSF-1R inhibitor targeting tenosynovial giant cell tumors in patients. This important presentation promises to reveal the efficacy and safety profile of HMPL-653, an exciting new addition to HUTCHMED's portfolio.

Details of the Upcoming Presentations

Attendees will gain insights into:

  • HMPL-653 Phase I Study: This first-in-human trial will reveal initial findings and patient outcomes.
  • Fruquintinib Clinical Applications: Updated efficacy data for various cancers treated with fruquintinib will clarify its role in combined therapies.

About HUTCHMED

HUTCHMED is a pioneering biopharmaceutical company dedicated to discovering and commercializing targeted therapies for cancer and immunological diseases. Their commitment to transforming innovative drug candidates into readily available treatments is shown by their first medications being marketed in China as well as globally, including in the US and Europe.

Engagement and Community Outreach

HUTCHMED continues to connect with the healthcare community, sharing vital updates and engaging with industry stakeholders to broaden the impact of its groundbreaking therapies.

Frequently Asked Questions

What are the upcoming conferences for HUTCHMED?

HUTCHMED will present at the 2025 World Conference on Lung Cancer and the CSCO Annual Meeting 2025.

What is savolitinib?

Savolitinib is a potent MET tyrosine kinase inhibitor effective for certain lung cancer patients.

What new data will be released for HMPL-653?

The upcoming presentations will include new clinical data from a Phase I study of HMPL-653 targeting tenosynovial giant cell tumors.

What is HUTCHMED's mission?

HUTCHMED is committed to developing and commercializing innovative therapies for cancer and immunological conditions.

Where can I find more information about HUTCHMED's projects?

More details can be accessed through HUTCHMED's official website or social media channels.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Flux Expands AI Platform to Prove Engineering ROI

Updated Category News Views 0

Navigating the AI Maze: Flux's New Pathways Ever feel like these engineering platforms speak a language of their own? Flux's latest expansion finally offers a translator that matters. It's all about decoding whether your AI investment is delivering the goods. Engineering leaders now have more than just fluffy metrics; Flux breaks down real code-based evidence to show if...

Continue Reading
Riverside Theatre Appoints Seasoned CFO for Growth Phase

Updated Category News Views 0

Change Is Afoot at Riverside Theatre Down in Vero Beach, amid the sun-drenched coziness of Florida’s Treasure Coast, something’s cooking that has nothing to do with sunshine: Riverside Theatre snagged itself a new Chief Financial Officer. As nonprofits go, this one’s not a backyard operation—it’s the largest independent professional theatre in the entire state....

Continue Reading
Hi-Tech's Dubai Chocolate Adds Flavor to Sales Surge

Updated Category News Views 0

Ever found a protein shake that tastes like a candy bar from the future? Well, Hi-Tech Pharmaceuticals is banking on their new Dubai Chocolate flavor to hit that sweet spot. This isn't your typical powdered shake game; Hi-Tech's been cranking the flavor dial ever since they introduced their Precision Protein® line back in 2016. They've carved out a niche with unique...

Continue Reading
EZ Elephant's Ladder-Free Gutter Fix Debuts at Expo

Updated Category News Views 0

A New Leaf in Gutter Maintenance From the ground up, EZ Elephant is redefining how we tackle gutter maintenance. Picture it: never having to teeter on that wobbly ladder again just to unclog your gutters. This American-made solution, showcased at the Western Roofing Expo from September 27–29, 2026, is a game changer. Check out Booth #834 to see this marvel of innovation...

Continue Reading
First Lady Steals NYSE Show, Investors Eye Stakes

Updated Category News Views 0

Something's Buzzing at the Big Board Walk over to Wall Street on September 23rd, and guess what you get? A lot more than just stock tickers blinking away. First Lady Melania Trump’s stealing the show at the New York Stock Exchange to kick off the inaugural IMPERIA Summit. She’s there to sound the opening bell and lead the charge in a summit that's focused on the...

Continue Reading
Class Action Lawsuit Targets Lincoln Educational Services

Updated Category News Views 0

Legal Maneuver Against Lincoln Educational Services Here we go again—another day, another lawsuit. The recent flap with Lincoln Educational Services Corporation (NASDAQ: LINC) is as classic as any market rug pull. Stepping into the spotlight, Wolf Haldenstein Adler Freeman & Herz LLP—a courtroom icon since 1888—has announced a class action lawsuit against Lincoln....

Continue Reading
Charter Next Generation Taps Herndon as Financial Chief

Updated Category News Views 10

Bringing New Leadership to Charter Next Generation It's an intriguing time to be watching Charter Next Generation (CNG) as they just added a heavyweight to their executive team. Todd Herndon, a veteran with more than three decades of financial savvy, steps in as their new Chief Financial Officer. This is like a football team drafting a star quarterback right before the...

Continue Reading
Epiclay: Game Changer for Sculptors Debuts

Updated Category News Views 0

Epiclay™ Brings New Energy to Sculpting World Folks, if ever there was a time to break the mold, it’s now, and Ace of Clay’s got us covered with Epiclay™—a fresh take on polymer clay that’s turning heads in the sculpture circuit. Over four long years, Ace of Clay, a brand that's gathered a rather colorful following through captivating sculptures and detailed...

Continue Reading
SureDone's Taska AI: Transforming Marketplace Listings

Updated Category News Views 0

Revolutionizing the E-Commerce Landscape Wake up and smell the innovation, folks! SureDone is rolling out Taska AI, a tool that's set to declutter the chaotic world of enterprise marketplace listings. It's no bed of roses for sellers out there, dealing with diverse channel demands and post-submission hiccups. Taska AI steps in as the seasoned handyman these sellers...

Continue Reading
Saudi Arabia Unveils CEER's Flagship Electric Vehicles

Updated Category News Views 4

CEER's Ambitious Leap in Automotive Innovation There's a new kid on the automotive block, and it's making some serious noise. Straight out of Jeddah, CEER has just taken the wraps off their flagship electric sedan and SUV, dubbed the EXOBOT. No small beans here—this is a full-throttle, Saudi-driven pitch into the global automotive circus. And why not? There's oil in...

Continue Reading

Top 5 Most Recently Viewed Articles

CommerceWest Bank Ranks Among Top Public Banks Nationwide

Updated Category News Views 132

CommerceWest Bank Earns Prestigious National Recognition CW Bancorp (CWBK), the parent company of CommerceWest Bank, has received a remarkable honor by ranking 6th among the Top 20 Best Performing Banks with under $2 billion in assets nationwide. This accolade showcases the Bank's outstanding financial health, operational excellence, and steadfast dedication to...

Continue Reading
Cellectis Advances Eti-cel for r/r NHL: Exciting Updates on Research

Updated Category News Views 147

Cellectis Announces Development Plans for Eti-cel in r/r NHL Cellectis, a clinical-stage biotechnology company, is making significant strides in its journey to transform cancer therapies. At a recent major medical conference, the company presented the latest encouraging results from its Phase 1 clinical trial regarding Eti-cel, an innovative treatment for patients with...

Continue Reading
Medline Extends Agreement for Medical Supply Distribution

Updated Category News Views 502

Medline's Continued Partnership with MMCAP Infuse Medline, a leading provider of medical-surgical products and supply chain solutions, has recently secured an important contract extension from MMCAP Infuse. This extension is crucial as it allows Medline to maintain its role as a pivotal distributor of essential medical and surgical supplies to local and state...

Continue Reading
Sify Data Centers in Chennai and Noida Obtain NVIDIA Certification

Updated Category News Views 130

Sify Data Centers in Chennai and Noida Achieve NVIDIA Certification In a significant milestone for Sify Infinit Spaces Limited, the data center arm of Sify Technologies Limited (NASDAQ: SIFY), their facilities in Chennai and Noida have recently received the prestigious NVIDIA DGX-Ready certification for liquid cooling. This achievement underscores Sify's commitment to...

Continue Reading
SunnyWhale Launches Innovative FinWhale Robot at CES 2026

Updated Category News Views 150

SunnyWhale Introduces the FinWhale Robot Dispenser Revolutionizing Pool Care With Autonomous Solutions Imagine having a pool that essentially maintains itself. Gone are the days of spending weekends fussing over water chemistry and feeling anxious before vacations. At CES 2026, this dream turns into a reality as SunnyWhale introduces the FinWhale Robot Dispenser. This...

Continue Reading